ATE445597T1 - ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß - Google Patents

ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß

Info

Publication number
ATE445597T1
ATE445597T1 AT04007878T AT04007878T ATE445597T1 AT E445597 T1 ATE445597 T1 AT E445597T1 AT 04007878 T AT04007878 T AT 04007878T AT 04007878 T AT04007878 T AT 04007878T AT E445597 T1 ATE445597 T1 AT E445597T1
Authority
AT
Austria
Prior art keywords
sup
oxo
pyrrolidine derivatives
useß
pharmaceutical
Prior art date
Application number
AT04007878T
Other languages
German (de)
English (en)
Inventor
Edmond Differding
Benoit Kenda
Benedicte Lallemand
Alain Matagne
Philippe Michel
Patrick Pasau
Patrice Talaga
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9886259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE445597(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE445597T1 publication Critical patent/ATE445597T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT04007878T 2000-02-23 2001-02-21 ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß ATE445597T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0004297.8A GB0004297D0 (en) 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Publications (1)

Publication Number Publication Date
ATE445597T1 true ATE445597T1 (de) 2009-10-15

Family

ID=9886259

Family Applications (5)

Application Number Title Priority Date Filing Date
AT04007878T ATE445597T1 (de) 2000-02-23 2001-02-21 ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß
AT04008270T ATE488500T1 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidin-derivate, verfahren zu ihrer herstellung und ihre verwendung.
AT04007733T ATE325093T1 (de) 2000-02-23 2001-02-21 ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß
AT01925354T ATE304999T1 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung
AT01940256T ATE282592T1 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung

Family Applications After (4)

Application Number Title Priority Date Filing Date
AT04008270T ATE488500T1 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidin-derivate, verfahren zu ihrer herstellung und ihre verwendung.
AT04007733T ATE325093T1 (de) 2000-02-23 2001-02-21 ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß
AT01925354T ATE304999T1 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung
AT01940256T ATE282592T1 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung

Country Status (43)

Country Link
US (12) US6713635B2 (enEXAMPLES)
EP (8) EP1447399B9 (enEXAMPLES)
JP (5) JP4081275B2 (enEXAMPLES)
KR (4) KR100816185B1 (enEXAMPLES)
CN (5) CN1740151A (enEXAMPLES)
AT (5) ATE445597T1 (enEXAMPLES)
AU (5) AU5214401A (enEXAMPLES)
BE (1) BE2016C012I2 (enEXAMPLES)
BG (4) BG65923B1 (enEXAMPLES)
BR (2) BRPI0108664B8 (enEXAMPLES)
CA (2) CA2401033C (enEXAMPLES)
CO (2) CO5271667A1 (enEXAMPLES)
CU (2) CU23293B7 (enEXAMPLES)
CY (3) CY1105517T1 (enEXAMPLES)
CZ (3) CZ304420B6 (enEXAMPLES)
DE (5) DE60119397T2 (enEXAMPLES)
DK (3) DK1265862T3 (enEXAMPLES)
EG (1) EG24375A (enEXAMPLES)
ES (5) ES2264060T3 (enEXAMPLES)
FR (1) FR16C1001I2 (enEXAMPLES)
GB (1) GB0004297D0 (enEXAMPLES)
HK (2) HK1052695B (enEXAMPLES)
HU (4) HUP0300196A3 (enEXAMPLES)
IL (5) IL150842A0 (enEXAMPLES)
IS (8) IS2119B (enEXAMPLES)
LT (1) LTC1265862I2 (enEXAMPLES)
LU (1) LU92993I2 (enEXAMPLES)
ME (1) ME00595B (enEXAMPLES)
MX (2) MXPA02008206A (enEXAMPLES)
MY (4) MY140593A (enEXAMPLES)
NL (1) NL300815I2 (enEXAMPLES)
NO (6) NO324051B1 (enEXAMPLES)
NZ (1) NZ520448A (enEXAMPLES)
PL (3) PL213669B1 (enEXAMPLES)
PT (2) PT1452524E (enEXAMPLES)
RO (2) RO121559B1 (enEXAMPLES)
RS (2) RS50454B (enEXAMPLES)
RU (5) RU2292336C2 (enEXAMPLES)
SA (2) SA01220027B1 (enEXAMPLES)
SI (1) SI1265862T1 (enEXAMPLES)
TW (2) TW200626544A (enEXAMPLES)
WO (2) WO2001064637A1 (enEXAMPLES)
ZA (2) ZA200205671B (enEXAMPLES)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365093B2 (en) * 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) * 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
CA2438930A1 (en) * 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
DE60229267D1 (de) * 2001-08-10 2008-11-20 Ucb Pharma Sa Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
PL370529A1 (en) * 2001-10-08 2005-05-30 Ucb, S.A. Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
CN1604776A (zh) 2001-10-16 2005-04-06 记忆药物公司 作为用于治疗神经病综合症的pde-4抑制剂的4-(4-烷氧基-3-羟基苯基)-2-吡咯烷酮衍生物
AU2003242538A1 (en) * 2002-05-14 2003-11-11 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
DE602004023051D1 (de) * 2003-01-13 2009-10-22 Ucb Pharma Sa Hydrierungskatalysatoren
US7132552B2 (en) * 2003-02-03 2006-11-07 Teva Pharmaceutical Industries, Ltd. Process for producing levetiracetam
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
TR200503397T1 (tr) * 2003-03-18 2007-03-21 Hetero Drugs Limited Levetirasetam'ın yeni kristal formları.
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
JP2006523710A (ja) 2003-04-16 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ4インヒビター
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
WO2005023763A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
CN1882535B (zh) * 2003-09-24 2011-05-11 Ucb药物股份有限公司 2-氧代-1-吡咯烷衍生物的制备方法
ZA200604410B (en) * 2003-12-02 2008-09-25 Ucb Sa Imidazole derivatives, processes for preparing them and their uses
DE602005003472T2 (de) 2004-06-11 2008-09-25 Ucb Pharma, S.A. Verfahren zur herstellung von 2-oxo-1-pyrrolidinderivaten durch intramolekulare allylierung
EA011765B1 (ru) * 2004-06-21 2009-06-30 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Получение прегабалина и родственных соединений
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
CN101166737A (zh) 2004-10-20 2008-04-23 记忆药物公司 磷酸二酯酶4抑制剂
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
WO2006128692A2 (en) 2005-06-01 2006-12-07 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
CA2620243C (en) * 2005-09-15 2015-01-20 Ucb Pharma, S.A. 4-substituted pyrrolidin-2-ones and their use
JP2007153755A (ja) * 2005-12-01 2007-06-21 Gifu Univ プロリン類縁体
WO2007065634A1 (en) * 2005-12-07 2007-06-14 Ucb Pharma, S.A. 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
LV13630B (en) * 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
WO2007141002A1 (en) * 2006-06-08 2007-12-13 Ucb Pharma, S.A. Co-crystals of pyrrolidinones
PT2462990E (pt) * 2006-06-15 2014-04-02 Ucb Pharma Gmbh Composição farmacêutica com efeito anticonvulsivo sinergístico
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
SI2076508T1 (sl) * 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
EP2152262A2 (en) * 2007-04-27 2010-02-17 UCB Pharma, S.A. New heterocyclic derivatives useful for the treatment of cns disorders
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
PT2273975E (pt) * 2008-03-03 2014-07-17 Ucb Pharma Sa Processos de preparação e utilizações terapêuticas de soluções farmacêuticas
US7741327B2 (en) * 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US20110212944A1 (en) * 2008-07-01 2011-09-01 Julie Liu 2-oxo-1-pyrrolidine derivatives
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
JP4644881B2 (ja) 2008-09-19 2011-03-09 高砂香料工業株式会社 ルテニウム錯体の製造方法
WO2010044878A1 (en) 2008-10-16 2010-04-22 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
US8722715B2 (en) * 2008-11-07 2014-05-13 NovaBay Pharmaceuticals Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
CA2741038C (en) * 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
US10172805B2 (en) * 2008-11-18 2019-01-08 Ucb Biopharma Sprl Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
FR2939311A1 (fr) * 2008-12-08 2010-06-11 Oreal Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
EP2393483B1 (en) 2009-02-09 2017-06-28 UCB Biopharma SPRL Pharmaceutical compositions comprising brivaracetam
US8846411B2 (en) * 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
US20120171125A1 (en) 2009-08-07 2012-07-05 Ucb Pharma, S.A. Methods for Enhancing the Cognitive Function
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
US8487591B1 (en) 2009-12-31 2013-07-16 Cirrus Logic, Inc. Power control system with power drop out immunity and uncompromised startup time
PL2491045T3 (pl) 2009-10-23 2016-06-30 Ucb Biopharma Sprl Pochodne 2-okso-1-pirolidynyloimidazotiadiazolu
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
FR2961101B1 (fr) 2010-06-09 2013-01-25 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
FR2961099B1 (fr) 2010-06-09 2012-06-15 Oreal Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
FR2961098A1 (fr) 2010-06-09 2011-12-16 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
MX346185B (es) 2010-11-15 2017-03-10 Agenebio Inc Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
AU2012214303A1 (en) * 2011-02-09 2013-09-12 The Johns Hopkins University Methods and compositions for improving cognitive function
JP5969003B2 (ja) 2011-04-18 2016-08-10 ユセベ ファルマ ソシエテ アノニム 2−オキソ−1−イミダゾリジニルイミダゾチアジアゾール誘導体
AU2012315671B2 (en) 2011-09-30 2017-07-20 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
JP2015504054A (ja) * 2011-12-27 2015-02-05 バイオ−ファーム ソリューションズ カンパニー リミテッド 多発性硬化症の治療または予防に使用されるフェニルカルバメート化合物
TW201408293A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
WO2014052896A1 (en) 2012-09-28 2014-04-03 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3406594A1 (en) 2012-12-07 2018-11-28 Merck Sharp & Dohme Corp. Biocatalytic transamination process
WO2014087367A2 (en) * 2012-12-09 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and its associated complications
US9970929B2 (en) 2013-01-18 2018-05-15 Ark Diagnostics, Inc. Voriconazole immunoassays
ES2674704T3 (es) 2013-02-13 2018-07-03 Ark Diagnostics, Inc. Inmunoensayos de posaconazol
WO2014160502A1 (en) 2013-03-13 2014-10-02 Tufts University Uridine nucleoside derivatives, compositions and methods of use
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
JP6453632B2 (ja) * 2013-12-05 2019-01-16 株式会社日本触媒 環状アミドアクリレート含有組成物およびその製造方法
JP6465634B2 (ja) * 2013-12-05 2019-02-06 株式会社日本触媒 環状アミド基含有重合体
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
KR102502485B1 (ko) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
CN104098497B (zh) * 2014-06-17 2016-04-13 王庚禹 一种新的酰胺类化合物
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
WO2016131947A1 (en) 2015-02-20 2016-08-25 Ucb Biopharma Sprl Combination treatment
CA2984832A1 (en) 2015-05-25 2016-12-01 Esteve Quimica S.A. Processes to produce brivaracetam
CN106365986B (zh) * 2015-07-21 2019-01-08 苏州鹏旭医药科技有限公司 化合物及其制备方法和在合成布瓦西坦中的用途
CN106279074B (zh) * 2015-05-25 2018-06-26 苏州鹏旭医药科技有限公司 一种化合物及其制备方法和在合成布瓦西坦中的用途
EP3310785B1 (en) 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3954394A1 (en) 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release
WO2017076737A1 (en) 2015-11-03 2017-05-11 Ucb Biopharma Sprl Continuous process for preparing brivaracetam
PL3371150T3 (pl) 2015-11-03 2022-01-17 UCB Biopharma SRL Sposób wytwarzania briwaracetamu
CN106748748B (zh) * 2015-11-10 2021-08-24 成都国为生物医药有限公司 一种布瓦西坦的制备方法及其中间体
CN105646319B (zh) * 2015-12-30 2018-05-18 佛山市隆信医药科技有限公司 一种布瓦西坦的制备方法
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
WO2017192665A1 (en) 2016-05-03 2017-11-09 The Regents Of The University Of California Inhibitors of ires-mediated protein synthesis
RU2629117C1 (ru) * 2016-06-14 2017-08-24 Сизов Владимир Владимирович Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
CN107513031B (zh) * 2016-06-16 2022-08-02 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP4397652A3 (en) 2017-01-20 2024-10-23 The Regents of the University of California 3-(phenyl)-2-(aminomethyl)-1-phenyl-2-propen-1-one derivatives as inhibitors of the n-terminal domain of the androgen receptor for treating prostate cancer
CN106866483A (zh) * 2017-02-05 2017-06-20 苏州鹏旭医药科技有限公司 布瓦西坦的晶型c及其制备方法
WO2018141276A1 (zh) * 2017-02-05 2018-08-09 苏州鹏旭医药科技有限公司 布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN108658831B (zh) * 2017-03-30 2021-11-05 江苏豪森药业集团有限公司 2-氧代-1-吡咯烷衍生物或其盐的制备方法
MX393879B (es) 2017-04-24 2025-03-24 Tesaro Inc Métodos de preparación de niraparib.
IL305317B1 (en) 2017-06-30 2025-07-01 Univ California Compositions and methods for modulating hair growth
CA3081548A1 (en) 2017-09-26 2019-04-04 The Regents Of The University Of California Compositions and methods for treating cancer
CN107793342A (zh) * 2017-10-19 2018-03-13 丽珠集团新北江制药股份有限公司 一种布瓦西坦的制备方法
CN107721896A (zh) * 2017-10-19 2018-02-23 丽珠集团新北江制药股份有限公司 一种布瓦西坦的中间体的制备方法
IL274920B2 (en) 2017-11-30 2024-01-01 Centurion Biopharma Corp Maytansinoid-based drug delivery systems
EP4344747A3 (en) 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
WO2019152536A1 (en) 2018-01-30 2019-08-08 The Regents Of The University Of California Inhibitors of the wnt/beta-catenin pathway
CN108147988B (zh) * 2018-02-13 2020-10-02 扬州奥锐特药业有限公司 一种高手性纯度内酰胺化合物的制备方法
CN108530402B (zh) * 2018-04-10 2020-06-26 浙江工业大学 一种(R)-3-丙基-γ-丁内酯的制备方法
EP3566760A1 (en) * 2018-05-07 2019-11-13 Universite Libre De Bruxelles Method for nucleating crystals from a solution in a capillary tube
CA3097818A1 (en) 2018-05-08 2019-11-14 UCB Biopharma SRL 1-imidazothiadiazolo-2h-pyrrol-5-one derivatives
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN110615744B (zh) 2018-06-20 2023-01-06 上海朴颐化学科技有限公司 一种布瓦西坦中间体及其制备方法
EP3813841B1 (en) 2018-06-29 2025-08-13 The Regents Of The University Of California New molecular tweezers against neurological disorders and viral infections
RU2699669C1 (ru) * 2018-07-04 2019-09-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы N-карбамоилметил-4-фенил-2-пирролидона
SG11202100429TA (en) 2018-07-27 2021-02-25 California Inst Of Techn Cdk inhibitors and uses thereof
WO2020081836A1 (en) 2018-10-17 2020-04-23 The Regents Of The University Of California Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
CN113929707A (zh) 2018-10-31 2022-01-14 尹图赛利有限公司 稠合杂环苯并二氮杂䓬衍生物及其用途
CA3117350A1 (en) 2018-12-04 2020-06-11 Metys Pharmaceuticals AG Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio
EP3944739A4 (en) 2019-02-25 2023-06-21 The Regents of the University of California CARBON-CARBON BOND FRAGMENTATION PROCESSES
CN109932442A (zh) * 2019-03-04 2019-06-25 成都美域高制药有限公司 一种布瓦西坦异构体的检测方法
EP3947387B1 (en) 2019-03-25 2024-10-23 California Institute Of Technology Prmt5 inhibitors and uses thereof
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
CN110357752A (zh) * 2019-08-15 2019-10-22 中国工程物理研究院化工材料研究所 一种快速制备均匀包覆含能材料的方法
RU2732245C1 (ru) * 2019-08-30 2020-09-14 Ооо "Валента-Интеллект" Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
CN110551050A (zh) * 2019-09-02 2019-12-10 南通大学 一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
US10781170B1 (en) 2019-10-21 2020-09-22 Divi's Laboratories Ltd. Process for preparing Brivaracetam
US20230100559A1 (en) 2020-01-07 2023-03-30 The Trustees Of Princeton University Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism
WO2021142221A1 (en) 2020-01-10 2021-07-15 The Regents Of The University Of California Compositions and methods for the treatment of neurodegenerative diseases
US20230174460A1 (en) 2020-04-21 2023-06-08 President And Fellowes Of Harvard College Afmt analogs and their use in methods of treating parkinson's disease
LV15614A (lv) * 2020-07-30 2022-02-20 Latvijas Organiskās Sintēzes Institūts 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
CA3191164A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
US20230365583A1 (en) 2020-08-10 2023-11-16 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
CA3191166A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
IL301627A (en) * 2020-10-06 2023-05-01 De Shaw Res Llc LACTAM COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
US20230399304A1 (en) 2020-10-23 2023-12-14 Dana-Farber Cancer Institute, Inc. Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
WO2022133237A2 (en) 2020-12-18 2022-06-23 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
WO2022140289A1 (en) 2020-12-21 2022-06-30 Cornell University Peptide-linked drug delivery system
US20240132480A1 (en) 2021-01-08 2024-04-25 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
US11400074B1 (en) 2021-02-01 2022-08-02 Divi's Laboratories Ltd. Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
US11384050B1 (en) * 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
CN114948953A (zh) * 2021-06-29 2022-08-30 四川大学华西医院 一种杂原子取代芳香类化合物及其盐的用途
CN113511994B (zh) * 2021-08-16 2023-03-21 江苏八巨药业有限公司 一种左乙拉西坦的制备方法
CN114634437B (zh) * 2022-03-29 2023-05-30 武汉氟本氘合新材料科技有限公司 一种布瓦西坦的简易制备方法
US11884623B2 (en) 2022-05-23 2024-01-30 Divi's Laboratories Ltd. Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
WO2024013209A1 (en) 2022-07-13 2024-01-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
WO2024049236A1 (ko) * 2022-08-31 2024-03-07 고려대학교 산학협력단 키랄 감마 락탐 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법
WO2024163711A1 (en) 2023-02-02 2024-08-08 Osmoses Inc. Norbornyl benzocyclobutene ladder polymer composite membranes for fluid separation
CN116041240B (zh) 2023-02-17 2024-04-09 扬州奥锐特药业有限公司 布立西坦中间体的不对称催化氢化合成方法
EP4431086A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide
WO2025078883A2 (en) 2023-05-06 2025-04-17 Prepaire Labs Limited Organic compound (oxime) to combat chemical warfare agents
TW202525266A (zh) 2023-09-18 2025-07-01 美商旗艦先鋒創新有限責任(Vii)公司 可電離類脂質組成物及其治療用途
WO2025072893A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US20250162981A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD92031A (enEXAMPLES) *
DE92031C (enEXAMPLES)
US2836599A (en) * 1957-03-07 1958-05-27 Aerojet General Co Nu-(carboxyalkyl) dinitro lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
US4008281A (en) 1973-12-03 1977-02-15 Monsanto Company Asymmetric catalysis
SU731892A3 (ru) 1974-10-15 1980-04-30 Монсанто Компани (Фирма) Способ получени оптических изомеров -замещенных -ациламидопропионовых кислот
DE3361609D1 (en) * 1982-03-24 1986-02-06 Prodes Sa New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
DE3371510D1 (en) * 1982-03-24 1987-06-19 Prodes Sa New 2-oxo-1-pyrrolidineacetic acid esters, their methods of production and therapeutic compositions containing the same
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
CN1015542B (zh) * 1984-05-15 1992-02-19 尤西比公司 (R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
JPS60166692A (ja) 1984-09-28 1985-08-29 Kazuo Achinami 新規不斉還元試薬
CH666891A5 (de) * 1985-11-26 1988-08-31 Lonza Ag 4-alkoxy-2-oxo-pyrrolidin-1-yl-essigsaeure-c(1)-c(4)-alkylester, deren herstellung und verwendung.
DE3719873A1 (de) * 1987-06-13 1988-12-29 Basf Ag Verfahren zur herstellung von itaconsaeurediestern und itaconsaeure
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5171892A (en) 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
EP0645135A1 (de) * 1993-09-29 1995-03-29 Solco Basel AG Hämodialysat enthaltendes Sonnenschutzmittel
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
TW544311B (en) * 1998-08-06 2003-08-01 Daiichi Seiyaku Co Therapeutic or preventive agent for intractable epilepsies
CZ20001055A3 (cs) * 1998-10-02 2000-08-16 Dupont Pharmaceuticals Company Nové laktamové inhibitory metaloproteázy
CA2392879C (en) 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same

Also Published As

Publication number Publication date
CN1303066C (zh) 2007-03-07
ATE488500T1 (de) 2010-12-15
YU63202A (sh) 2005-09-19
AU778510B2 (en) 2004-12-09
BE2016C012I2 (enEXAMPLES) 2020-01-30
MY139420A (en) 2009-09-30
NO2016005I2 (no) 2016-03-08
YU63102A (sh) 2005-09-19
EP1477478A3 (en) 2004-11-24
CZ304702B6 (cs) 2014-09-03
SA01220078B1 (ar) 2006-10-29
IS7923A (is) 2005-06-29
RU2005125645A (ru) 2007-02-20
US6713635B2 (en) 2004-03-30
NO324485B1 (no) 2007-10-29
JP4938259B2 (ja) 2012-05-23
RO121559B1 (ro) 2007-11-30
IL150842A0 (en) 2003-02-12
NO2023025I1 (no) 2023-06-20
KR20020075927A (ko) 2002-10-07
RS50454B (sr) 2010-03-02
NO20023997D0 (no) 2002-08-22
US8034958B2 (en) 2011-10-11
US20120035239A1 (en) 2012-02-09
US6806287B2 (en) 2004-10-19
RU2005125569A (ru) 2007-02-20
CU23293B7 (es) 2008-06-30
CN1179944C (zh) 2004-12-15
CN1404470A (zh) 2003-03-19
BG65923B1 (bg) 2010-05-31
IL170181A (en) 2010-11-30
CO5271667A1 (es) 2003-04-30
US7217826B2 (en) 2007-05-15
EP1477478A2 (en) 2004-11-17
HK1052695A1 (en) 2003-09-26
RO121597B1 (ro) 2007-12-28
NZ520448A (en) 2004-03-26
PT1447399E (pt) 2006-09-29
CA2401033A1 (en) 2001-08-30
RU2006125756A (ru) 2008-01-27
MXPA02008206A (es) 2004-04-05
MY140593A (en) 2009-12-31
NL300815I2 (enEXAMPLES) 2016-07-27
US20050159475A1 (en) 2005-07-21
MXPA02008056A (es) 2004-08-12
JP4121744B2 (ja) 2008-07-23
BR0108657A (pt) 2003-04-29
TW200626545A (en) 2006-08-01
US20040087646A1 (en) 2004-05-06
KR20020075926A (ko) 2002-10-07
JP4769756B2 (ja) 2011-09-07
EP1447399A1 (en) 2004-08-18
US7692028B2 (en) 2010-04-06
HUP0300196A2 (hu) 2003-06-28
HK1052516B (zh) 2006-02-10
HUP0300196A3 (en) 2005-10-28
DE60143493D1 (de) 2010-12-30
EP1447399B1 (en) 2006-05-03
DE60119397T2 (de) 2007-04-19
CY2016022I2 (el) 2016-10-05
CZ304420B6 (cs) 2014-04-30
JP2007182459A (ja) 2007-07-19
US6969770B2 (en) 2005-11-29
HU229514B1 (en) 2014-01-28
JP2003523996A (ja) 2003-08-12
IL166768A (en) 2010-04-15
MY138966A (en) 2009-08-28
LTPA2016013I1 (lt) 2016-05-25
CU23201A3 (es) 2007-04-06
CA2401048A1 (en) 2001-09-07
KR100720784B1 (ko) 2007-05-23
CN1404469A (zh) 2003-03-19
PL210121B1 (pl) 2011-12-30
HU0500902D0 (en) 2005-12-28
IS7920A (is) 2005-06-29
US20080097109A1 (en) 2008-04-24
TW200626544A (en) 2006-08-01
NO324051B1 (no) 2007-08-06
CO5280059A1 (es) 2003-05-30
CY2016022I1 (el) 2016-10-05
CA2401048C (en) 2009-01-20
DK1447399T3 (da) 2006-08-28
IS7921A (is) 2005-06-29
HUP0204526A2 (hu) 2003-04-28
LTC1265862I2 (lt) 2023-09-11
DE60140222D1 (de) 2009-11-26
ATE304999T1 (de) 2005-10-15
RU2002124865A (ru) 2004-01-10
CZ20022850A3 (cs) 2003-02-12
RU2355680C2 (ru) 2009-05-20
PL365159A1 (en) 2004-12-27
IL166768A0 (en) 2006-01-15
US8492416B2 (en) 2013-07-23
EP1577295A1 (en) 2005-09-21
BG65783B1 (bg) 2009-11-30
BRPI0108664B8 (pt) 2021-05-25
AU2001252144C1 (en) 2008-03-20
BG107004A (bg) 2003-04-30
JP4081275B2 (ja) 2008-04-23
US20050171187A1 (en) 2005-08-04
NO2016005I1 (no) 2016-03-08
AU2001252144B2 (en) 2005-04-28
DK1265862T3 (da) 2006-01-30
FR16C1001I1 (fr) 2016-07-01
MEP6109A (en) 2011-12-20
RS50455B (sr) 2010-03-02
CN1208319C (zh) 2005-06-29
US20040192757A1 (en) 2004-09-30
CA2401033C (en) 2008-07-29
CY1109718T1 (el) 2014-08-13
AU2005200717B2 (en) 2007-05-17
EP1452524B1 (en) 2009-10-14
US20100222576A1 (en) 2010-09-02
FR16C1001I2 (fr) 2017-02-03
RU2292336C2 (ru) 2007-01-27
DE60113514T2 (de) 2006-05-18
IL150757A0 (en) 2003-02-12
PL213669B1 (pl) 2013-04-30
ME00595B (me) 2011-12-20
BRPI0108664B1 (pt) 2016-07-26
EP1477478B1 (en) 2010-11-17
PL359388A1 (en) 2004-08-23
US20050171188A1 (en) 2005-08-04
IS6481A (is) 2002-07-23
BG109297A (en) 2006-06-30
US6911461B2 (en) 2005-06-28
AU5214401A (en) 2001-09-03
BG107016A (en) 2003-04-30
KR20050091112A (ko) 2005-09-14
NO20053645L (no) 2002-10-22
ATE282592T1 (de) 2004-12-15
MY127149A (en) 2006-11-30
HUS1600017I1 (hu) 2020-02-28
EP1452524A1 (en) 2004-09-01
EG24375A (en) 2009-03-19
EP1265862B1 (en) 2005-09-21
KR100681580B1 (ko) 2007-02-09
NO20023995D0 (no) 2002-08-22
IS2119B (is) 2006-06-15
CN1740151A (zh) 2006-03-01
IS7918A (is) 2005-06-29
BG65803B1 (bg) 2009-12-31
AU7389601A (en) 2001-09-12
KR100816185B1 (ko) 2008-03-21
AU2005200718B2 (en) 2007-05-24
US6784197B2 (en) 2004-08-31
IS7919A (is) 2005-06-29
US6858740B2 (en) 2005-02-22
WO2001062726A3 (en) 2002-01-17
US20030120080A1 (en) 2003-06-26
IS2754B (is) 2011-09-15
ES2334998T3 (es) 2010-03-18
CZ20022849A3 (cs) 2003-02-12
WO2001062726A2 (en) 2001-08-30
IL150842A (en) 2008-06-05
US20040092576A1 (en) 2004-05-13
ES2231501T3 (es) 2005-05-16
JP2006022108A (ja) 2006-01-26
IS7922A (is) 2005-06-29
PL212197B1 (pl) 2012-08-31
IS2176B (is) 2006-12-15
HK1052516A1 (en) 2003-09-19
HK1052695B (zh) 2005-05-06
EP1263727B1 (en) 2004-11-17
SA01220027B1 (ar) 2006-09-19
ES2248307T3 (es) 2006-03-16
WO2001064637A1 (en) 2001-09-07
US20040116507A1 (en) 2004-06-17
LU92993I2 (fr) 2016-05-11
AU2005200718A1 (en) 2005-03-17
GB0004297D0 (en) 2000-04-12
RU2291860C2 (ru) 2007-01-20
DE60107216D1 (de) 2004-12-23
KR20050090090A (ko) 2005-09-12
EP1263727A1 (en) 2002-12-11
NO20023997L (no) 2002-10-22
EP1577296A1 (en) 2005-09-21
DE60113514D1 (de) 2005-10-27
JP2006022107A (ja) 2006-01-26
AU2005200717A1 (en) 2005-03-17
ES2264060T3 (es) 2006-12-16
HUP0204526A3 (en) 2005-03-29
ZA200205837B (en) 2003-11-04
IS6472A (is) 2002-07-16
ES2355140T3 (es) 2011-03-23
US7358276B2 (en) 2008-04-15
EP1447399B9 (en) 2006-10-18
PT1452524E (pt) 2010-01-18
CY1105517T1 (el) 2010-07-28
CN1740150A (zh) 2006-03-01
DE60119397D1 (de) 2006-06-08
ATE325093T1 (de) 2006-06-15
CN1680314A (zh) 2005-10-12
RU2291860C3 (ru) 2017-11-16
BR0108664A (pt) 2003-04-29
NO20023995L (no) 2002-10-21
EP1604979A1 (en) 2005-12-14
DK1452524T3 (da) 2010-03-01
EP1265862A2 (en) 2002-12-18
US20030040631A1 (en) 2003-02-27
ZA200205671B (en) 2003-11-10
HU230270B1 (hu) 2015-11-30
JP2003528828A (ja) 2003-09-30
KR100759145B1 (ko) 2007-09-14
NO20053644L (no) 2002-10-22
DE60107216T2 (de) 2005-11-03
SI1265862T1 (sl) 2006-02-28

Similar Documents

Publication Publication Date Title
ATE445597T1 (de) ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1452524

Country of ref document: EP